Development

EULAR Data Show Similarity of Samsung Bioepis Adalimumab Biosimilar to Humira

June 9th 2022

By Skylar Jeremias

Article

Data showing the clinical outcomes of Samsung Bioepis’ biosimilar referencing Humira (adalimumab) were shared at the European Congress of Rheumatology’s annual meeting, EULAR 2022.

New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says

May 30th 2022

By Laura Joszt

Article

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability, the US market is entering a new phase of biosimilar use.

New Data Show Bioequivalence for Alvotech Stelara Biosimilar

May 25th 2022

By Skylar Jeremias

Article

Alvotech released new data demonstrating the equivalence of its ustekinumab biosimilar (AVT04) to the reference product (Stelara) in patients with plaque psoriasis.

How Biosimilars Are Making Big Pharma More Eco-Friendly

May 24th 2022

By Skylar Jeremias

Article

As drug companies continue to follow the growing trend adopting more environmentally friendly and socially conscious frameworks, many are choosing to highlight their biosimilar portfolios as an example of their efforts.

Alvotech Announces Positive Phase 1 Results for Ustekinumab Biosimilar

May 16th 2022

By Skylar Jeremias

Article

In a pharmacokinetic study, Alvotech’s ustekinumab biosimilar referencing Stelara was shown to have comparable safety and efficacy to the reference product, according to the company’s preliminary results.

Pfizer Settles 2 Lawsuits, Starts Another Over Etanercept Biosimilar in Australia

May 16th 2022

By Skylar Jeremias

Article

After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit against 5 companies over the development of Brenzys, an etanercept biosimilar, in Australia.

Biocon Revenue Up 21% Thanks to Biosimilar, Generic Drug Successes

May 11th 2022

By Skylar Jeremias

Article

Biocon’s total revenue for the fourth quarter of the 2022 fiscal year was up 21% from the same period in the prior year, largely due to significant growth in sales for the company’s biosimilar and generic drugs.

Contributor: The Enemy of Your Enemy Should Be Your Friend – Why Biosimilars Companies Should Collaborate

May 9th 2022

By Ivo Abraham, PhD

Article

Biosimilar manufacturers should consider working together to overcome some of the barriers that prevent biosimilars from entering the market and obtaining market share, according to Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board.

Amgen Biosimilars See Increased Sales as Reference Product Sales Erode

May 7th 2022

By Skylar Jeremias

Article

Amgen’s earnings report for the first quarter of 2022 reveals that as some of its biosimilars experienced increased sales, its sales for reference products that are facing biosimilar competition decreased.

Coherus Biosciences Terminates Deal With Innovent for Avastin Biosimilar

May 6th 2022

By Skylar Jeremias

Article

During the Coherus Biosciences earnings call, the company announced that it was terminating its licensing agreement with Innovent Biologics for Byvasda, a bevacizumab biosimilar candidate referencing Avastin.